Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the stock. Separately, Chardan Capital lowered their price objective on shares of Immuneering from $16.00 to $12.00 and set a […]
More Stories
OpenAI Looking to Hire ‘Head of Preparedness’ to Tackle AI Dangers
By Naveen Athrappully OpenAI is seeking to hire a candidate for the post of “Head of Preparedness” to tackle dangers...
Washington Offers 15-Year Security Guarantee to Ukraine as Part of Peace Plan, Zelenskyy Says
By Guy Birchall Washington has offered a 15-year security guarantee to Kyiv as part of a proposed peace plan, Ukrainian...
Kremlin Says Ukraine Tried to Attack Putin’s Residence, Peace Deal Stance Under Review
By Jack Phillips Ukrainian forces attempted to strike Russian President Vladimir Putin’s residence in the Russian city of Novgorod on...
BofA CEO Calls Economy ‘Pretty Solid’ but Warns Consumer Pullback Is Top Risk for 2026
By Tom Ozimek U.S. economic growth remains on solid footing heading into 2026, but the outlook hinges on whether American...
Top 10 Investment Accounting Software & Other Related Software
Managing complex investment portfolios can be hectic most of the time, as a small mistake can lead to a huge...
Top 10 Richest K-Pop Idols in 2026
Do you also like K-pop or Korean pop? Then this article is for you. Let’s start. In this blog, you...